VTGN - VistaGen Therapeutic...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $0.67 | Open | $0.69 |
| Volume | 421.1K | Market Cap | 37.42M |
| Yield | Last Dividend |
| VistaGen Therapeutics Reports Fiscal 202... | 02/13/20 |
| SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing... | |
| VistaGen Therapeutics Receives FDA Clear... | 01/30/20 |
| SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing... | |
| VistaGen and Baylor College of Medicine ... | 12/19/19 |
| SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 19, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical compan... | |
| VistaGen Up on Fast Track Designation fo... | 12/11/19 |
| The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock s... | |
| Vistagen Therapeutics (NASDAQ:VTGN) Down... | 11/17/19 |
| William Blair downgraded shares of Vistagen Therapeutics (NASDAQ:VTGN) from an outperform rating to a market perform rating in a research report sent ... | |
| The Daily Biotech Pulse: Amarin Gets Una... | 11/15/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) ... | |
| VistaGen Reports Topline Phase 2 Results... | 11/14/19 |
| SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN ), a clinical-stage biopharmaceutical company developi... | |
| VistaGen Therapeutics Reports Fiscal 202... | 11/07/19 |
| SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN ), a clinical-stage biopharmaceutical company developin... | |
| VistaGen Therapeutics Expands European P... | 10/28/19 |
| SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing... | |
| The Daily Biotech Pulse: European Cheer ... | 07/30/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) ... | |
| The Daily Biotech Pulse: Obseva Reports ... | 05/03/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Al... | |
| Vistagen Shares Fall Under $1 After Depr... | 05/02/19 |
| Vistagen Therapeutics Inc (NASDAQ: VTGN ) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatm... | |
| ARCA biopharma leads healthcare gainers;... | 05/02/19 |
| No summary available. | |
| VistaGen's AV-101 flunks mid-stage depre... | 05/02/19 |
| No summary available. | |
| ABMD, FLR and W among premarket losers | 05/02/19 |
| No summary available. | |
| VistaGen nabs Australian patent covering... | 03/28/19 |
| No summary available. | |
| Vistgen And Relmada: Competitors In Depr... | 03/20/19 |
| No summary available. | |
| VistaGen Therapeutics (VTGN) Investor Pr... | 03/19/19 |
| No summary available. | |
| Mallinckrodt and Aerie Pharmaceuticals a... | 02/26/19 |
| No summary available. | |
| VistaGen prices stock offering at $1; sh... | 02/26/19 |
| No summary available. | |
| TRXC, MEDP and SAGE among premarket lose... | 02/26/19 |
| No summary available. | |
| VistaGen readies stock offering; shares ... | 02/25/19 |
| No summary available. | |
| VistaGen up 4% premarket on new U.S. pat... | 02/13/19 |
| No summary available. | |
| VistaGen Therapeutics misses by $0.11 | 02/12/19 |
| No summary available. | |
| VistaGen up 5% on preclinical AV-101 dat... | 01/31/19 |
| No summary available. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Ravi | 90.00 % | Follow |
| Trading Systems | Trading Systems | 83.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
